ВПРИВ

ВПРИВ Uses, Dosage, Side Effects, Food Interaction and all others data.

ВПРИВ is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, ВПРИВ has also been investigated for use in Type 3 Gaucher disease.

Table Of contents

• ВПРИВ
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	ВПРИВ
Generic	Velaglucerase alfa
Velaglucerase alfa Other Names	GA-GCB, Velaglucerasa alfa, Velaglucerase alfa
Type
Formula	C2532H3850N672O711S16
Weight	63000.0 Da (approximate)
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Russia
Last Updated:	September 19, 2023 at 7:00 am

Uses

ВПРИВ is an enzyme replacement therapy used for the long-term treatment of for pediatric and adult patients with type 1 Gaucher disease.

ВПРИВ is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.

ВПРИВ is also used to associated treatment for these conditions: Gaucher Disease, Type 1

How ВПРИВ works

ВПРИВ catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.

Food Interaction

No interactions found.

Volume of Distribution

The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight).

Half Life

11-12 minutes.

Clearance

Mean clearance ranges from 6.72 to 7.56 mL/min/kg.

Innovators Monograph

You find simplified version here ВПРИВ